February 7, 2018 / 12:44 PM / 7 months ago

Biogen stops developing Tysabri to treat stroke after failed study

Feb 7 (Reuters) - Biogen Inc said on Wednesday it would stop developing Tysabri to treat acute ischemic stroke patients after the drug failed to meet the main goal of a mid-stage study.

Tysabri is already approved to treat multiple sclerosis. (Reporting by Manas Mishra in Bengaluru; Editing by Savio D'Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below